US · Healthcare · Biotechnology
EPS came in at -0.08 against a street estimate of -0.09 — a beat of 11.1%.
Analysts rate Immunitybio Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $12.75.
| Fund | Stake |
|---|---|
| BlackRock Inc | 3.22% |
| State Street Corp | 2.02% |
| Vanguard Portfolio Management, LLC | 1.69% |
| Vanguard Capital Management, LLC | 1.48% |
| D. E. Shaw & Co LP | 1.09% |
| Two Sigma Investments LLC | 1.05% |
| Geode Capital Management, LLC | 0.93% |
| Millennium Management LLC | 0.53% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • On October 14, 2026, the FDA expanded the approved indication for ANKTIVA® (nogapendekin alfa inbakicept-pmln). • ANKTIVA is appr | 2026-10-14 |
| Quarterly report · Q2 2026 IMMUNITYBIO, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $75.7 million in cash and cash equivalents as of June 30, 2026 (down from | 2026-08-04 |
| Results announced · Q3 2026 IMMUNITYБIO Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 net product revenue: $50.7 million, up 92% year-over-year and 15% sequentially • Fi | 2026-08-04 |
| Reg FD disclosure · Q3 2026 IMMUNITYBIO, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Marketing authorization for ANKTIVA® granted by Emirates Drug Establishment (EDE) of the Uni | 2026-07-30 |
| Shareholder vote results · Q2 2026 IMMUNITYBIO, INC. - 8-K FORM SUMMARY HEADLINE NUMBERS • Total shares outstanding: 1,047,345,861 common shares as of April 13, 2026 • Annual Meeting | 2026-06-10 |
| Material agreement · Q2 2026 IMMUNITYBIO, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: ImmunityBio, Inc. (NASDAQ: IBRX), Delaware corporation • Filing Date: May 18, 2026 • Agr | 2026-05-18 |
| Quarterly report · Q1 2026 IMMUNITYBIO, INC. - Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $205.2 million as of March 31, 2026, up from $88.3 million at Decemb | 2026-05-07 |
| Proxy statement · Q2 2026 IMMUNITYBIO, INC. PROXY STATEMENT SUMMARY CEO COMPENSATION • Richard Adcock (President and CEO) 2025 total compensation: $4,267,500 (includes base s | 2026-04-30 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immunitybio Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.